证券日报网1月21日讯，亚虹医药在接受调研者提问时表示，国家药品监督管理局药品审评中心(CDE) 已完成APL-1702的技术评审，公司将加快推进其上市审评审批工作，以期尽快获得上市批准。关于后 续进展，公司将严格按照《上海证券交易所科创板股票上市规则》等相关规定履行信息披露义务。 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 19, 2026 [1] Core Insights - 2025 marked a significant year for Chinese innovative drugs going global, with a total transaction amount of $135.655 billion, including $7 billion in upfront payments and 157 deals, setting historical highs. The trend continues into 2026, with notable licensing agreements from companies like Yilian Biotech and Rongchang Biotech, indicating strong global competitiveness for Chinese innovative drugs [2] - Major companies are increasingly investing in the small nucleic acid field, with significant acquisitions and clinical approvals. For instance, China National Pharmaceutical Group acquired Hangzhou Hejiya Biopharmaceutical for 1.2 billion RMB, while international firms like Novartis and GSK are also advancing in this area [3] - The GLP-1 market is expected to grow despite new pricing systems, with ongoing collaborations and new product launches anticipated in 2026. The market for GLP-1 drugs is projected to remain robust due to the large patient population for weight loss and diabetes [4] - The oral autoimmune drug market is gaining attention, with promising results from Takeda's new TYK2 inhibitor for psoriasis. Other domestic companies are also advancing in this space, exploring new targets for oral small molecules [5] - The brain-computer interface sector is poised for industrialization, with companies like Neuralink set to produce devices in 2026. Domestic advancements and regulatory support are enhancing the potential for this technology in medical applications [6] - The ZAP-X radiation therapy device is expected to capture a significant market share in China, with rapid growth projected in non-invasive tumor radiation treatment, driven by increasing clinical recognition and adoption [8] Summary by Sections Industry Trends - The pharmaceutical sector is witnessing a resurgence in interest towards innovative drugs, with a notable increase in the innovative drug index by 8.97% since early January 2026, outperforming the CSI 300 index by 6.77 percentage points [2] Company Recommendations - Recommended companies include: - **Yuekang Pharmaceutical** and **Sunshine Nuohua** in the small nucleic acid space - **Yahong Pharmaceutical** and **Yifang Biotechnology** in the autoimmune sector - **Zhongsheng Pharmaceutical** in the GLP-1 market - **Baiyang Pharmaceutical** for ZAP-X radiation therapy - **Meihao Medical** for brain-computer interface technology [10] Market Opportunities - The non-invasive tumor radiation treatment market is projected to grow from 27.2 billion RMB in 2018 to 59.4 billion RMB by 2024, with a compound annual growth rate of 13.9% [8]

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance fund efficiency while ensuring the safety of the raised funds and the implementation of investment projects [1][2]. Cash Management Overview - The company intends to use a maximum of RMB 1.2 billion (including the amount) of temporarily idle raised funds for cash management, with a validity period of 12 months from the date of the board's approval [2][8]. - The cash management aims to increase returns for the company and its shareholders while not affecting the normal operation of the fundraising investment projects [2][12]. Investment Details - The investment will focus on high-security, high-liquidity financial products sold by qualified financial institutions, including agreement deposits, time deposits, notice deposits, large certificates of deposit, structured deposits, and income certificates [4][8]. - The company will not use these funds for securities investment purposes [4]. Implementation and Oversight - The board has authorized the chairman to make investment decisions and sign relevant contracts within the approved limits and timeframe, with the finance department responsible for implementation [5][8]. - The company will adhere to strict regulatory requirements and maintain a separation of decision-making, execution, and supervision functions to ensure fund safety [10]. Impact on the Company - The use of temporarily idle raised funds for cash management is expected to improve fund efficiency and provide good investment returns for the company and its shareholders, without affecting daily cash flow needs or the normal operation of fundraising projects [12]. Opinions from Intermediaries - The sponsor, CITIC Securities Co., Ltd., has reviewed the cash management plan and found it compliant with relevant laws and regulations, expressing no objections to the company's decision [12].

证券代码：688176 证券简称：亚虹医药 公告编号：2026-002 江苏亚虹医药科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）于 2026 年 1 月 16 日召开第二届董事会第二十次会议，审议通过了《关于使用部分 暂时闲置募集资金进行现金管理的议案》，同意公司在保证不影响募集资金投资 项目实施、募集资金安全的前提下，使用部分暂时闲置募集资金进行现金管理， 用于购买安全性高、流动性好、有保本约定、具有合法经营资格的金融机构销售 的投资产品，使用期限自本次董事会审议通过之日起 12 个月内有效，在前述额 度及期限范围内，公司可以循环滚动使用。 董事会授权董事长在授权额度和期限内行使现金管理投资决策权并签署相 关合同文件，具体事项由公司财务部负责组织实施。保荐人中信证券股份有限公 司（以下简称"保荐人"）对上述事项出具了核查意见。本事项无需提交股东会 审议。现将公司本次使用部分闲置募集资金进行现金管 ...

中信证券股份有限公司关于江苏亚虹医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）为江苏亚虹 医药科技股份有限公司（以下简称"公司"、"亚虹医药"）首次公开发行股票 并上市的保荐人。根据《证券发行上市保荐业务管理办法》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》《上市公司募集资金监管规则》 《上海证券交易所科创板股票上市规则》等相关法律、法规和规范性文件的规定， 对亚虹医药使用部分暂时闲置募集资金进行现金管理事项进行了核查，核查情况 及核查意见如下： 一、募集资金基本情况 （三）资金来源 | 发行名称 | 公司首次公开发行股票 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 募集资金到账时间 | 2021 年 12 月 31 | | | 日 | | | | | | 募集资金总额 | 252,780.00 | | 万元 | | | | | | | 募集资金净额 | 万元 238,059.22 | | | | | | ...

Core Viewpoint - The company, Yahuang Pharmaceutical, has announced the approval of a proposal to use up to 1.2 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [1] Group 1: Financial Management - The board of directors approved the use of idle funds for cash management, with a maximum limit of 1.2 billion yuan [1] - The investment products will be purchased from financial institutions that offer high safety, good liquidity, and capital protection agreements [1] - The usage period for these funds is valid for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] Group 2: Impact on Operations - This decision will not affect the progress of the fundraising investment projects or the normal production and operation of the company [1]

证券之星消息，1月15日化学制药板块较上一交易日下跌1.4%，向日葵领跌。当日上证指数报收于 4112.6，下跌0.33%。深证成指报收于14306.73，上涨0.41%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300452 | 山河药辅 | 16.85 | 20.01% | 41.42万 | | 6.70亿 | | 301075 | 多瑞医药 | 62.71 | 11.48% | 2.65万 | | 1.65 Z | | 688176 | 亚虹医药 | 13.16 | 7.69% | 26.47万 | | 3.45亿 | | 300401 | 化园生物 | 16.52 | 3.57% | 1 50.30万 | | 8.28亿 | | 000739 | 普洛药业 | 18.13 | 3.30% | 27.08万 | | 4.87亿 | | 002923 | 润都股份 | 13.04 | 3.16% | 9.42万 | | 1.23亿 | | ...

自愿披露关于APL-2401完成I期临床试验 首例受试者入组公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688176 证券简称：亚虹医药 公告编号：2026-001 江苏亚虹医药科技股份有限公司 二、该药品研发及其他相关情况 APL-2401为全球同步研发的1类创新药，其国际多中心临床试验设计及申报资料符合国际临床试验技术 标准体系要求，成功纳入国家药监局于2025年9月12日发布的《关于优化创新药临床试验审评审批有关 事项的公告（2025年第86号）》规定的"30日通道"，并以仅22个工作日获得批准，成为全国首批获得此 项新政审批通过的项目之一，具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《江 苏亚虹医药科技股份有限自愿披露关于APL-2401临床试验申请获得国家药品监督管理局批准的公告》 （公告编号：2025-046）。该研究已于近日成功完成I期临床首例受试者给药，自获批后仅15个工作日 即实现首例给药，成为新政下首批临 ...

北京商报讯（记者 丁宁）1月8日晚间，亚虹医药（688176）发布公告称，近日，公司自主研发的APL- 2401 在FGFR2/3驱动的晚期实体瘤患者中开展的I期临床试验完成首例受试者入组。 公告显示，APL-2401是公司自主研发的高选择性成纤维生长因子受体2/3（FGFR2/3）双靶点小分子抑 制剂，有望为晚期实体瘤（例如尿路上皮癌、胆管癌、子宫内膜癌、胃癌、乳腺癌、卵巢癌、非小细胞 肺癌和其他特定实体瘤）患者提供一种新的治疗选择。 ...

Group 1 - Jinli Permanent Magnet expects a net profit of 660 million to 760 million yuan for 2025, representing a year-on-year growth of 127% to 161% [1] - Wens Foodstuffs anticipates a net profit of 5 billion to 5.5 billion yuan for 2025, a decrease of 40.73% to 46.12% compared to the previous year [2] - New Open Source plans to repurchase shares worth 40 million to 50 million yuan, with a maximum repurchase price of 25.77 yuan per share [3] Group 2 - Fosun Pharma's subsidiary has had a drug registration application accepted for a new drug targeting ALK-positive non-small cell lung cancer [4] - Leike Film reported a net profit of -86 million yuan for the first three quarters of 2025, indicating a potential annual loss [5] - Crown Stone Technology's application for a specific issuance of A-shares has been accepted by the Shanghai Stock Exchange [6] Group 3 - Dongxin Technology has completed the business registration change for its subsidiary, Lishuan Technology, and has invested 211 million yuan in it [7] - Tianci Materials has increased its commodity futures hedging business limit from 150 million to 300 million yuan [8] - Gaode Infrared's actual controller has reduced his shareholding by 0.54%, bringing his stake down to 62.95% [9] Group 4 - Tianyong Intelligent expects a net profit of 10 million to 15 million yuan for 2025, marking a turnaround from losses [10][11] - China Merchants Energy anticipates a net profit of 6 billion to 6.6 billion yuan for 2025, an increase of 17% to 29% year-on-year [18] - Guangdong Electric Power A's Huizhou Power Plant's Unit 5 has been put into commercial operation, with an investment of 8.05 billion yuan [19] Group 5 - Jianghuai Automobile reported a 42.24% year-on-year increase in sales volume for December 2025 [25] - China Pharmaceutical's subsidiary has received a drug registration certificate for a new medication [26] - TianNeng Co. plans to use up to 12 billion yuan of its own funds for entrusted wealth management [27] Group 6 - Luoyang Huizhong reported a 10.55% month-on-month decrease in sales revenue from live pigs for December 2025 [28] - Baolidi expects a net profit of 145 million to 152 million yuan for 2025, a year-on-year increase of 27.17% to 33.30% [30] - Changchun High-tech's subsidiary has had a melatonin granule registration application accepted [31] Group 7 - Zhongmin Energy reported a 4.46% year-on-year decrease in cumulative on-grid electricity for 2025 [32] - Huaxin Electronics reported a 7.79% year-on-year decrease in consolidated operating revenue for December 2025 [35] - Xiamen Airport reported a 2.79% year-on-year increase in passenger throughput for December 2025 [36] Group 8 - Baiyun Airport reported a 12.27% year-on-year increase in passenger throughput for December 2025 [37] - Pulaike has received a new veterinary drug registration certificate for a chewable tablet [38] - Yunnan Energy Holdings' subsidiary has reduced its stake to 84% after a capital increase [39] Group 9 - Gansu Energy Chemical's new thermal power project has successfully completed trial operation [41] - Zhenghong Technology reported a significant decrease in sales revenue from live pigs for December 2025 [42] - Huasheng Lithium Battery is planning to issue H-shares for listing on the Hong Kong Stock Exchange [43] Group 10 - Jincheng Mining has signed a mining production contract with an estimated total price of approximately 510 million yuan [44] - Microchip Biotech has received approval for clinical trials of a new drug for pancreatic cancer [45] - Yahon Pharmaceutical has completed the first patient enrollment for a Phase I clinical trial of its drug [46]